indication

Inflammation

Competitive landscape

as of 2026-07-01
Competitive set
2
1 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
19 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 24 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugUnknown
Minocycline
Pipeline · Phase 4
Phase 42 trials
OwnerPakistan Institute of Living and Learning
Protection—

Market size

prevalence as a range, not a number